Retatrutide For Weight Loss
Retatrutide for Weight Loss: What the Phase 2 Trial Found
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
Retatrutide for weight loss was studied in a phase 2 trial, and this page from Peptara Labs (peptaralabs.io) reports what it found: participants in the highest dose group showed a mean body weight change of about 24.2 percent at 48 weeks (Jastreboff et al., 2023).
This page is general educational information, research-use framing only, not medical advice. Retatrutide is investigational and not approved for human use.
What does the trial report on retatrutide and weight loss?
The phase 2 trial reported a mean body weight change of up to about 24.2 percent at 48 weeks in the highest-dose group (Jastreboff et al., 2023).
This came from a randomized, double-blind, placebo-controlled phase 2 study of adults with obesity, published in the New England Journal of Medicine (Jastreboff et al., 2023, doi:10.1056/NEJMoa2301972). The trial compared several dose groups with placebo. The largest mean reduction, about 24.2 percent, was seen in the highest dose group at week 48. Retatrutide remains investigational, and the numbers here describe what researchers measured.
For context within the same drug class, semaglutide showed about 15 percent mean weight loss in STEP 1 (Wilding et al., 2021), and tirzepatide reached up to about 22.5 percent in SURMOUNT-1 (Jastreboff et al., 2022).
How does retatrutide work in the body?
Retatrutide is a triple agonist that activates the GLP-1, GIP, and glucagon receptors with one molecule (Jastreboff et al., 2023).
The first two targets, GLP-1 and GIP, are incretin pathways shared with tirzepatide, which is a dual GLP-1 plus GIP agonist (Jastreboff et al., 2022). Retatrutide adds a third arm: glucagon receptor activity. Glucagon signaling is linked to energy expenditure and hepatic fat handling, which is the proposed reason for adding it to an incretin backbone. The phase 2 paper describes this three-receptor design as the mechanistic basis for the reported changes (Jastreboff et al., 2023). Human evidence beyond phase 2 is still limited, so longer-term mechanism-to-outcome data are not yet established.
How did weight change across the trial's dose groups?
Mean weight change rose across the trial's dose groups, with the largest change in the highest dose group (Jastreboff et al., 2023).
The table below shows the reported mean change for each group in the phase 2 publication.
| Group | Reported mean body weight change at 48 weeks | Source |
|---|---|---|
| Placebo | about 2.1 percent | Jastreboff et al., 2023 |
| Lowest dose group | about 8.7 percent | Jastreboff et al., 2023 |
| Second dose group | about 17.1 percent | Jastreboff et al., 2023 |
| Third dose group | about 22.8 percent | Jastreboff et al., 2023 |
| Highest dose group | about 24.2 percent | Jastreboff et al., 2023 |
Values are approximate group means as reported in the phase 2 paper (Jastreboff et al., 2023).
Is retatrutide approved or still investigational?
Retatrutide is investigational and has no marketing approval; it has been studied in clinical trials only (Jastreboff et al., 2023).
The 2023 publication describes phase 2 results, an earlier stage than the large phase 3 programs that supported approval of other agents in this class. Because it is investigational, there is no approved label, no approved indication, and no established real-world safety profile outside trial conditions. Anything described on this page reflects trial reporting.
How does retatrutide compare to tirzepatide and semaglutide?
Across separate trials, the reported peak mean weight change was highest for retatrutide, then tirzepatide, then semaglutide, though these came from different studies and cannot be directly compared head to head.
| Compound | Receptor targets | Reported peak mean weight change | Trial |
|---|---|---|---|
| Semaglutide | GLP-1 | about 15 percent | Wilding et al., 2021 (STEP 1) |
| Tirzepatide | GLP-1 + GIP | about 22.5 percent | Jastreboff et al., 2022 (SURMOUNT-1) |
| Retatrutide | GLP-1 + GIP + glucagon | about 24.2 percent | Jastreboff et al., 2023 |
These figures come from different trial designs, populations, and durations, so the grid shows reported ranges, not a controlled comparison. A direct head-to-head trial would be needed to compare them properly. Such a head-to-head between tirzepatide and semaglutide exists (Frias et al., 2021, SURPASS-2), but retatrutide has not been compared to them in the same study.
What happens to weight after stopping this drug class?
Published data on related GLP-1-class agents report meaningful weight regain after treatment stops (Wilding et al., 2022; Aronne et al., 2024).
In the STEP 1 extension, participants regained a large share of lost weight after semaglutide was withdrawn (Wilding et al., 2022). SURMOUNT-4 reported weight regain after tirzepatide was stopped (Aronne et al., 2024). This pattern is consistent with adaptive thermogenesis, the body's tendency to defend a higher weight after loss (Rosenbaum and Leibel, 2010). Retatrutide-specific withdrawal data are limited given its investigational stage, so durability remains an open question.
Keep reading
Related research and verification
Retatrutide results timeline
What the trials measured over time.
Retatrutide side effects
The adverse events the phase 2 trial reported.
Retatrutide half life
The roughly 6-day half-life the research reports.
Retatrutide vs tirzepatide
How the two trial programs compare.
Retatrutide complete guide
Mechanism, trial data and research handling in one guide.
Retatrutide For Weight Loss: FAQ
What was the biggest weight change reported for retatrutide?
The phase 2 trial reported a mean body weight change of about 24.2 percent at 48 weeks in the highest dose group (Jastreboff et al., 2023). This is a group mean from one trial.
What makes retatrutide different from tirzepatide?
Tirzepatide activates two receptors, GLP-1 and GIP (Jastreboff et al., 2022). Retatrutide activates a third, the glucagon receptor, in addition to those two (Jastreboff et al., 2023).
Is retatrutide available as an approved medicine?
No. It is investigational and studied in clinical trials only, with no marketing approval described in the phase 2 publication (Jastreboff et al., 2023).
How long was the phase 2 trial?
The primary reported timepoint for the peak mean weight change was 48 weeks (Jastreboff et al., 2023).
Did weight return after related drugs were stopped?
Durability is unsettled. For related agents, published data report significant regain after treatment stopped (Wilding et al., 2022; Aronne et al., 2024). Retatrutide-specific data on this are limited.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, not medical advice. Research-grade material is not for human use.